title: Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
abstract: This study was designed to assess the efficacy and safety of gemcitabine, cisplatin and methylprednisolone (GEM-P) for patients with relapsed or refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma. Twenty-one patients were treated with gemcitabine (1000 mg/m2 d 1, 8 and 15), cisplatin (100 mg/m2 d 15) and methylprednisolone (1000 mg d 1-5) given every 28 d. Of these, 20 patients were evaluable for response. The median age was 38 years (range 17-64 years). Histological subtypes were: nodular sclerosing HD (n = 10), diffuse large B cell (n = 5), T cell-rich B cell (n = 2), follicular (n = 2), mantle cell (n = 1) and enteropathy-associated T-cell lymphoma (n = 1). The median remission duration prior to receiving GEM-P was only 42 d. The overall objective response rate was 80%[95% confidence interval (CI): 56-94%], including five complete and 11 partial responses. GEM-P induced responses in all histological subtypes, primary progressive disease and patients who had received a previous autograft. The only grade 3-4 toxicity was myelosuppression. However, no cases of febrile neutropenia or haemorrhage with thrombocytopenia were encountered. Median survival has not yet been reached and survival probability at 1 year was 60.8% (95% CI: 31.9-80.5%). In conclusion, GEM-P is a novel combination salvage therapy for poor-prognostic primary progressive or multiply relapsed lymphoma patients. It has clinically significant activity with a favourable toxicity profile.
authors.affiliation: Department of Medicine, Royal Marsden Hospital, London, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Chau
authors.forename: Mark
authors.initials: M
authors.lastname: Harries
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
authors.forename: Mark
authors.initials: M
authors.lastname: Hill
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Ross
authors.forename: Caroline D
authors.initials: CD
authors.lastname: Archer
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Norman
authors.forename: Andrew
authors.initials: A
authors.lastname: Wotherspoon
authors.forename: Dow Mu
authors.initials: DM
authors.lastname: Koh
authors.forename: Kairen
authors.initials: K
authors.lastname: Gill
authors.forename: Maggie
authors.initials: M
authors.lastname: Uzzell
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Prior
authors.forename: Daniel
authors.initials: D
authors.lastname: Catovsky
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000401:mortality; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy / Q000401:mortality; D016399:Lymphoma, T-Cell / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D012008:Recurrence; D015996:Survival Rate; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D008775:Methylprednisolone; D000093542:Gemcitabine